louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06944704: Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice
Official title: Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hepatobiliary Disorders
Keywords: Jaundice
Pentoxifylline
TAC
TNF-α
Bilirubin
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2025-04-25
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice


Eligibility criteria: Inclusion Criteria:

* Patients age 18-70 years old.
* Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.

Exclusion Criteria:

* Pregnancy.

  * Nursing mothers.
  * Patients with increased indirect bilirubin level.
  * Patients who have Gilbert syndrome or Crigler Najjar syndrome.
  * Patients with Child Paugh C score (10-15 point).
  * History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
  * Recent hemorrhage.
  * Patients who have risk factors potentially complicated by hemorrhage.
  * Taking anticoagulants or antiplatelet therapy.

Primary outcomes:
measure: Change in total antioxidant capacity (TAC) level,
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
measure: Change in tumor necrosis factor alpha (TNF-α)
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.
Secondary outcomes:
measure: Follow up of liver function
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to12 weeks.
measure: Adverse events and toxicity
timeFrame: up to 12 weeks
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Pharmacy, Tanta University
Study officials:
References:
Clinical trial NCT04173104: PET and MRI Imaging of Brain Tumors Using [18F]PARPi
Official title: Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Brain Tumor
Brain Cancer
Keywords: Brain cancer
18FPARPi
PET scan
MRI
Memorial Sloan Kettering Cancer Center
19-311
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2019-11-21
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer


Eligibility criteria: Inclusion Criteria:

* Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan)
* Age \>/= 18 years
* Minimum at least one brain lesion size \>/= 1.5cm diameter
* Scheduled to undergo treatment at MSK
* Willingness to sign informed consent
* Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines

Exclusion Criteria:

* Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla)
* Pregnancy or breast-feeding women

Primary outcomes:
measure: SUVmax measurements
timeFrame: Up to 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Robert Young, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00624104: VLDL-triglyceride Under Acute Hyperinsulinaemia
Official title: VLDL-triglyceride Under Acute Hyperinsulinaemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: VLDL
Kinetics
Hyperinsulinaemia
Obesity
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2008-02-26
Enrollment: 16
Sex: MALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males with diabetes from departments out-patient clinic. Control group of healthyt volunteers

Brief summary: The purpose of the study is to investigate and compare the lipid metabolism in lean and obese individuals. We want to investigate the effect of postprandial hyperinsulinaemia on VLDL-triglyceride metabolism


Eligibility criteria: Inclusion Criteria:

- Written consent

Exclusion Criteria:

* Known diseases
* Alcohol abuse
* Smoker
* Regular use of medicine

Primary outcomes:
measure: VLDL metabolism
timeFrame: Few hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus C
country: Denmark
facility: Department of Endocrinology M, Aarhus Hospital
Study officials:
References:
Clinical trial NCT04901104: Long-term Prognosis of Patients With Sepsis After Immunotherapy
Official title: Long-term Prognosis After Thymosin Alpha 1 Treatment in Patients With Sepsis: A Multicenter Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Long-term Effects of Thymosin Alpha 1 Treatment
Keywords: long-term
thymosin alpha 1
sepsis
immunotherapy
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2021-05-25
Enrollment: 900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sepsis patients who discharged from hospital after recovery in the TESTS study

Brief summary: Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.

Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.


Eligibility criteria: Inclusion Criteria:

* Sepsis patients in the TESTS study Patients who discharged from hospital after recovery

Exclusion Criteria:

* None

Primary outcomes:
measure: three years mortality
timeFrame: 3 years
Secondary outcomes:
measure: Recurrence rate of sepsis
timeFrame: 5 years
measure: one year mortality
timeFrame: 1 year
measure: Five years mortality
timeFrame: 5 years
measure: short form 36 questionnaire
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01774604: Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Official title: Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Post-ERCP Acute Pancreatitis
Keywords: Post ERCP acute pancreatitis
Post Fine Needle Aspiration (FNA) acute pancreatitis
Indomethacin
Rectal Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2013-01-24
Enrollment: 449
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.


Eligibility criteria: Inclusion Criteria:

1. Scheduled for an ERCP at Dartmouth-Hitchcock
2. Age greater than 18 years old
3. Ability to provide written informed consent

Exclusion Criteria:

1. Inability to provide written informed consent
2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis
3. Current ongoing acute pancreatitis
4. Previously documented allergy to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5. Contra-indication to NSAID therapy (creatinine level \>1.4 or active peptic ulcer disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)
6. Pregnant or nursing mothers

Primary outcomes:
measure: Number of Patients Who Developed Acute Pancreatitis
timeFrame: From randomization to 30 days after ERCP
Secondary outcomes:
measure: Number of Patients Who Developed Severe Pancreatitis
timeFrame: From randomization to 30 days after ERCP
measure: Number of Patients Who Developed Moderately Severe Pancreatitis
timeFrame: From randomization to 30 days after ERCP
measure: Number of Patients Who Developed Mild Pancreatitis
timeFrame: From randomization to 30 days after ERCP
measure: Number of Patients Who Developed Gastrointestinal Bleeding
timeFrame: From randomization to 30 days after ERCP
measure: Number of Patient Deaths
timeFrame: From randomization to 30 days after ERCP
measure: Number of Patients With 30 Days Hospital Re-admission
timeFrame: From randomization until 30 days after ERCP
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: John M Levenick, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Levenick JM, Gordon SR, Fadden LL, Levy LC, Rockacy MJ, Hyder SM, Lacy BE, Bensen SP, Parr DD, Gardner TB. Rectal Indomethacin Does Not Prevent Post-ERCP Pancreatitis in Consecutive Patients. Gastroenterology. 2016 Apr;150(4):911-7; quiz e19. doi: 10.1053/j.gastro.2015.12.040. Epub 2016 Jan 9.
Clinical trial NCT04873804: The Effect of Transcranial Direct Stimulation on Cognitive Functions of Healthy Adults
Official title: The Effect Of Transcranial Direct Stimulation Applied To The Dorsolateral Prefrontal Cortex And Posterior Parietal Cortex İn Cognitive Function, Mood And Proprioception İn Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Symptom
Healthy
Keywords: tDCS
Dorsolateral Prefrontal Cortex
Posterior Parietal Cortex
Cognitive Function
Lead sponsor: Medipol University
Sponsor class: OTHER
First posted: 2021-05-05
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Background: Transcranial direct current stimulation(tDCS) has been used to improve cognitive functions in healthy young adults.

Purpose: To investigate the effect of TDCS application on different cortex regions on cognitive function.

Methods: Sixty individuals aged 18-30 were included in the study. The participants were randomly divided into the left dorsolateral prefrontal cortex (Left DLPFC Group)(n=20), the right posterior parietal cortex (Right PPC Group)(n=20), and the sham group (Sham Group)(n=20). tDCS was applied for 20 minutes on weekdays for 2 weeks. The participants were evaluated in terms of cognitive functions with Neuropsychometric Test Battery before and after treatment.


Eligibility criteria: Inclusion Criteria:

* being 18-30 years old

Exclusion Criteria:

* alcohol and substance addiction
* previous mental illness
* having mental and cognitive problems
* a history of head trauma
* having cardiovascular disease.

Primary outcomes:
measure: Neuropsychiatric Test Battery
timeFrame: 3 weeks
measure: Beck Depression Scale
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Damla Ören
city: Istanbul
country: Turkey
facility: Medipol Mega Hospital
Study officials:
affiliation: Medipol University
name: Miray Budak, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medipol University
name: Lutfu Hanoglu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06528704: The Impact of Real Time Ventilation Feedback on Ventilation Rate and Tidal Volume During Cardiac Arrest.
Official title: The Impact of Real Time Ventilation Feedback on Ventilation Rate and Tidal Volume During Cardiac Arrest.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cardiac Arrest
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2024-07-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: During out-of-hospital cardiopulmonary resuscitation, patient are first ventilated without ventilation feedback (but with a flowsensor connected), hereafter patients are ventilated with the use of ventilation feedback.

Detailed description: During cardiac arrest, patients are intubated, ventilation is performed using a manual resuscitator. Hereafeter, a flowsensor is connected. During the first cycle, patients are ventilated without any feedback (whilst the sensor is recording the delivered ventilation). During the second cycle, realtime delivered flow is shown on the screen, informing the user on the delivered ventilation volume and ventilation rate. Data is saved automatically after use.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

Traumatic cardiac arrest Inability to intubate patient

Primary outcomes:
measure: Delivered ventilation frequency
timeFrame: 2 minutes
measure: Delivered ventilation volume
timeFrame: 2 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Knokke
country: Belgium
facility: AZ Zeno
state: West-Vlaanderen
city: Ghent
country: Belgium
facility: Ghent University Hospital
Study officials:
References:
Clinical trial NCT04979104: Hip Arthroplasty With SL Cementless
Official title: A Post-market Study Evaluating Clinical and Radiographic Early Outcomes pf Hip Arthroplasty With SL Cementless Stem.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hip Replacement
Keywords: Cementless femoral stem
Hip arthroplasty
Lead sponsor: Limacorporate S.p.a
Sponsor class: INDUSTRY
First posted: 2021-07-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients from Nemocnice Kyjov Hospital (CZ)

Brief summary: The study aims to evaluate the clinical, radiographical and patient-reported outcomes measurements up 3 years FU and to assess the survivorship of SL Cementless Stem after partial or total hip arthroplasty.


Eligibility criteria: Inclusion Criteria:

All patients that underwent to partial or total hip arthroplasty and implanted with SL cementless stem between Jan 2010 and Jan 2020 at Nemocnice Kyjov Hospital (CZ) in accordance with the indication for use of the product and site standard of practice.

Additional Inclusion criteria:

* Availability of patients' immediate post-operative radiograph (baseline) and of a number of follow-up x-rays that the Principal Investigator deems sufficient for an effective radiographic implant evaluation and stability assessment;
* Patient is willing and able to complete additional follow-up evaluations if needed after signing ICF.

Exclusion Criteria:

* Age \< 18 years;
* Female patients who are pregnant, nursing, or planning a pregnancy

Primary outcomes:
measure: Implant radiographic stability
timeFrame: 3 years FU
Secondary outcomes:
measure: Clinical outcomes
timeFrame: 6 weeks, 3 months, 1 year, 3 years after surgery
measure: Implant safety profile
timeFrame: 6 weeks, 3 months, 1 year, 3 years after surgery
Other outcomes:
Locations:
city: Kyjov
country: Czechia
facility: Nemocnice Kyjov Hospital
state: CZ Republic
Study officials:
References:
Clinical trial NCT06383104: Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus.
Official title: Combination of Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in the Clinical and Functional Improvement of Patients With Systemic Lupus Erythematosus. Randomised Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: System; Lupus Erythematosus
Keywords: Systemic lupus erythematosus
Physiotherapy
Joint pain
Range of motion
Functionality
Balance
Fatigue
Lead sponsor: Universidad Católica San Antonio de Murcia
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Introduction. Systemic lupus erythematosus is an autoimmune disease. The musculoskeletal system is affected in 90% of patients. The most common manifestations are myalgias, arthralgias and arthritis.

Objective. To analyse the efficacy of an intervention using myofascial techniques and proprioceptive neuromuscular facilitation in patients with systemic lupus erythematosus.

Methods. Randomised clinical study with 20 patients with systemic lupus erythematosus, randomised to an experimental and control group. The intervention will last 4 weeks, with a periodicity of 2 weekly sessions of 50 minutes each. The intervention of the experimental group will consist of a protocol using myofascial and proprioceptive neuromuscular facilitation techniques.

Expected results. Improvement of knee and ankle pain intensity, functional capacity, basic mobility skills, strength, balance, agility and fatigue.


Eligibility criteria: Inclusion Criteria:

* Subjects over 18 years of age
* With a medical diagnosis of systemic lupus erythematosus
* Who sign the informed consent form.

Exclusion Criteria:

* Patients with fever or acute phlebitis.
* Patients with recent lower limb fractures
* Amputees and people with neurological or cognitive impairments that prevent them from correctly understanding the questionnaires and performing the guided techniques.

Primary outcomes:
measure: Change from baseline joint pain after treatment and at 4 weeks
timeFrame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Secondary outcomes:
measure: Change from baseline functional capacity after treatment and at 4 weeks
timeFrame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
measure: Change from baseline functionality after treatment and at 4 weeks
timeFrame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
measure: Change from baseline joint pain after treatment and at 4 weeks
timeFrame: Screening visit, within the first seven days after treatment and after four weeks follow-up visit
Other outcomes:
Locations:
city: Murcia
country: Spain
facility: Universidad Católica San Antonio, Murcia
Study officials:
References:
Clinical trial NCT03107104: Triton Fundus Autofluorescence and Fluorescein Angiography
Official title: Topcon DRI OCT Triton (Plus) Fundus Autofluorescence and Fluorescein Angiography Image Quality Evaluation Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Medical Need for Fluorescein Angiography Imaging
Lead sponsor: Topcon Corporation
Sponsor class: INDUSTRY
First posted: 2017-04-11
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with medical need for FA imaging

Brief summary: Compare the image quality of the fundus autofluorescence and fluorescein angiography

Detailed description: The objectives of this study are to:

1. Compare the image quality of the fundus autofluorescence (FAF) photographs between DRI OCT Triton (plus) and TRC-50DX retinal camera.
2. Compare the image quality of the fluorescein angiography (FA) photographs between DRI OCT Triton (plus) and TRC-50DX retinal camera.

Eligibility criteria: Inclusion Criteria

1. Subjects must be at least 18 years of age
2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. Subjects who consent to, via clinic's standard FA consent form, and will undergo dye injection for FA imaging at the clinic visit based on medical need

Exclusion Criteria

1. Subjects unable to tolerate ophthalmic imaging
2. Subjects with ocular media not sufficiently clear to obtain acceptable fundus images
3. Patients with ocular motility dysfunction

Primary outcomes:
measure: Fundus autofluorescence image quality
timeFrame: 1 Minute
measure: Fluorescein angiography image quality at 120 seconds to 300 seconds after dye injection
timeFrame: 120 seconds to 300 seconds
measure: Fluorescein angiography image quality at greater than 300 seconds after dye injection
timeFrame: greater than 300 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Vitreous Retina Macula Consultants of New York
state: New York
Study officials:
affiliation: Topcon Corporation
name: Charles Riesman, MS
role: STUDY_CHAIR
References:
Clinical trial NCT06514404: Comparative Study of Empathy and Anxiety in the Different Academic Years, at the Beginning of Academic Year and Exam Period in Healthy Students.
Official title: Comparative Study of Empathy and Anxiety in the Different Academic Years, at the Beginning of Academic Year and Exam Period and the Relationship of These Variables With Personality at the University of León and Madrid in the Degree of Nursing, Physiotherapy and Podiatry.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Health Education
Health Promotion
Health Behavior
Keywords: health students
anxiety
empahty
assessment personality
Health behavior
Lead sponsor: Mayuben Private Clinic
Sponsor class: OTHER
First posted: 2024-07-23
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health science students are the target population of this study and the aim is to obtain data on their state and trait anxiety as well as its relationship with personality at the beginning of the academic year.

Brief summary: Students from different health science degrees will carry out a study on the variables of empathy, anxiety and personality profile.

Detailed description: Students from different health science degrees will carry out a study on the variables of empathy, anxiety and personality profile by means of validated questionnaires in order to compare them between different Spanish regions and in different courses to be able to see their evolution and characteristics.

Eligibility criteria: Inclusion Criteria:

* Men and women who are studying a health grade.
* Subjects that wish to participate in the study.

Exclusion Criteria:

* Students who do not wish to participate in the study.

Primary outcomes:
measure: Empathy Quotent
timeFrame: Through study completion, an average of 1 week
measure: State anxiety
timeFrame: Through study completion, an average of 1 week
measure: Anxiety as a trait
timeFrame: Through study completion, an average of 1 week
measure: Abbreviated personality questionnaire
timeFrame: Through study completion, an average of 1 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: